Глава 2. Розацеа

Noguera-Morel L., Hernández-Martin A., Torrelo A. Childhood rosacea and related disorders // Clin. Exp. Dermatol. 2021. Vol. 46. N. 3. P. 430–437. DOI: https://doi.org/10.1111/ced.14419. Epub 2020 Nov 20. PMID: 33217048.

Ohata C., Saruban H., Ikegami R. Granulomatous rosacea affecting the lacrimal and salivary glands // Arch. Dermatol. 2004. Vol. 140. N. 2. P. 240–242. DOI: https://doi.org/10.1001/archderm.140.2.240-b. PMID: 14967807.

O’Leary P., Kierland R.R. Pyoderma faciale // Arch. Dermatol. 1940. Vol. 41. N. 3. P. 451. DOI: https://doi.org/10.1001/archderm.1940.01490090003001.

Patterson C., Wilkinson J., Lewis F. Rosacea fulminans confined to the nose // J. Eur. Acad. Dermatol. Venereol. 2009. Vol. 23. N. 9. P. 1101–1102. DOI: https://doi.org/10.1111/j.1468–3083.2009.03098.x.

Plewig G., Jansen T. Rosacea disorders of epidermal appendages and related disorders // Dermatology in General Medicine. 5th ed. / Eds T.B. Fitzpatrick, I.M. Freedberg, A.Z. Eisen et al. New York, NY: McGraw-Hill, 1999. P. 785–792.

Plewig G., Jansen T., Kligman A.M. Pyoderma faciale. A review and report of 20 additional cases: is it rosacea? // Arch. Dermatol. 1992. Vol. 128. P. 1611–1617. DOI: https://doi.org/10.1001/archderm.1992.04530010049007.

Plewig G., Nikolowski J., Wolff H.H. Action of isotretinoin in acne rosacea and gram-negative folliculitis // J. Am. Acad. Dermatol. 1982. Vol. 6. P. 766–785. DOI: https://doi.org/10.1016/S0190-9622(82)70067-2.

Pogorzelska-Dyrbuś J., Sosnowski M., Szepietowski J.C. Rosacea fulminans with rhinophyma and severe eye complications in a young woman treated with isotretinoin // Postepy Dermatol. Alergol. 2021. Vol. 38. N. 5. P. 903–905. DOI: https://doi.org/10.5114/ada.2020.94743. Epub 2020 Apr 25. PMID: 34849142; PMCID: PMC8610035.

Rallis E., Korfitis C. Isotretinoin for the treatment of granulomatous rosacea: case report and review of the literature // J. Cutan. Med. Surg. 2012. Vol. 16. N. 6. P. 438–441. DOI: https://doi.org/10.1177/120347541201600615. PMID: 23149202.

Ranu H., Lee J., Hee T.H. Therapeutic hotline: successful treatment of Morbihan’s disease with oral prednisolone and doxycycline // Dermatol. Ther. 2010. Vol. 23. N. 6. P. 682–685. DOI: https://doi.org/10.1111/j.1529-8019.2010.01373.x. PMID: 21054712.

Razeghi S., Halvorson C.R., Gaspari A.A., Cross R.K. Successful treatment of localized pyoderma faciale in a patient with Crohn’s disease // Gastroenterol. Hepatol. (N.Y.). 2013. Vol. 9. N. 8. P. 541–543. PMID: 24719607; PMCID: PMC3981002.

Redd T.K., Seitzman G.D. Ocular rosacea // Curr. Opin. Ophthalmol. 2020. Vol. 31. N. 6. P. 503–507. DOI: https://doi.org/10.1097/ICU.0000000000000706. PMID: 33009083.

Saal R.C., Borda L.J., Hoffman M.L. et al. Treatment of granulomatous rosacea with adalimumab // JAAD Case Rep. 2023. Vol. 40. P. 89–91. DOI: https://doi.org/10.1016/j.jdcr.2023.08.017. PMID: 37771357; PMCID: PMC10523424.

Saki N., Amani M., Nezhad N.Z. et al. Efficacy and safety of topical brimonidine in dermatology: a review article // Dermatol. Ther. 2022. Vol. 35. N. 11. Article ID e15819. DOI: https://doi.org/10.1111/dth.15819. Epub 2022 Oct 3. PMID: 36097378.

Sánchez J.L., Berlingeri-Ramos A.C., Dueño D.V. Granulomatous rosacea // Am. J. Dermatopathol. 2008. Vol. 30. N. 1. P. 6–9. DOI: https://doi.org/10.1097/DAD.0b013e31815bc191. PMID: 18212536.

Sanz-Motilva V., Martorell Calatayud A., Rivera R., Vanaclocha-Sebastián F. Rosácea fulminans inducida por corticoides tópicos. Casos clinicos [Rosacea fulminans: report of two cases] // Rev. Med. Chil. 2012. Vol. 140. N. 5. P. 637–639. DOI: https://doi.org/10.4067/S0034-98872012000500013. PMID: 23096671. (In Spanish).

Schaller M., Almeida L.M.C., Bewley A. et al. Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel // Br. J. Dermatol. 2020. Vol. 182. N. 5. P. 1269–1276. DOI: https://doi.org/10.1111/bjd.18420. Epub 2019 Oct 16. PMID: 31392722; PMCID: PMC7317217.

Schaller M., Gonser L., Belge K. et al. Dual anti-inflammatory and anti-parasitic action of topical ivermectin 1% in papulopustular rosacea // J. Eur. Acad. Dermatol. Venereol. 2017. Vol. 31. N. 11. P. 1907–1911. DOI: https://doi.org/10.1111/jdv.14437. Epub 2017 Aug 29. PMID: 28653460.

Schewach-Millet M., Shpiro D., Trau H. Granulomatous rosacea // J. Am. Acad. Dermatol. 1988. Vol. 18. N. 6. P. 1362–1363. DOI: https://doi.org/10.1016/s0190-9622(88)80118-x. PMID: 2968381.

Schimpf A. Blepharitis et pareitis granulomatosa // Derm. Wschr. 1960. Vol. 141. P. 446.

Schimpf A. Dermatitis frontalis granulomatosa // Derm. Wschr. 1956. Vol. 133. P. 120.

Schimpf A. Dermatitis frontalis granulomatosa // Derm. Wschr. 1958. Vol. 138. P. 829–830.

Schimpf A. Dermatitis granulomatosa periorbitalis und Pareiitis granulomatosa // Derm. Wschr. 1959. Vol. 139. P. 288.

Schmidt J.B., Gebhart W., Raff M., Spona J. 13-Cis-retinoic acid in rosacea. Clinical and laboratory findings // Acta Derm. Venereol. (Stockh.). 1984. Vol. 64. P. 15–21.

Schmitz S., Zouboulis C.C. Pyoderma faciale (Rosacea fulminans) assoziiert mit Colitis ulcerosa // Z. Hautkr. 1995. Vol. 70. P. 939–940.

Seo J.I., Shin M.K. Lupus miliaris disseminatus faciei versus granulomatous rosacea: a case report // Case Rep. Dermatol. 2021. Vol. 13. N. 2. P. 321–329. DOI: https://doi.org/10.1159/000517209. PMID: 34248540; PMCID: PMC8255731.

Serarslan G., Makbule Kaya Ö., Dirican E. Scale and pustule on dermoscopy of rosacea: a diagnostic clue for demodex species // Dermatol. Pract. Concept. 2021. Vol. 11. N. 1. Article ID e2021139. DOI: https://doi.org/10.5826/dpc.1101a139. PMID: 33614217; PMCID: PMC7875658.

Shi H., Zhang E., Zhang M., Lin T. Narrow-band intense pulsed light as treatment for erythematotelangiectatic rosacea: a retrospective study // J. Drugs Dermatol. 2023. Vol. 22. N. 11. P. 1095–1098. DOI: https://doi.org/10.36849/JDD.4920. PMID: 37943269.

Siddiqui K., Stein Gold L., Gill J. The efficacy, safety, and tolerability of ivermectin compared with current topical treatments for the inflammatory lesions of rosacea: a network meta-analysis // Springerplus. 2016. Vol. 5. N 1. P. 1151. DOI: https://doi.org/10.1186/s40064-016-2819-8. PMID: 27504249; PMCID: PMC4956638.

Simental-Lara F., Ponce-Olivera R.M. Rosácea fulminante asociada con colitis ulcerativa. Caso clinico // Dermatol. Rev. Mex. 2014. Vol. 58. P. 471–475.

Smith K.W. Perioral dermatitis with histopathologic features of granulomatous rosacea: successful treatment with isotretinoin // Cutis. 1990. Vol. 46. N. 5. P. 413–415. PMID: 2148143.

Smith L.A., Meehan S.A., Cohen D.E. Rosacea fulminans with extrafacial lesions in an elderly man: successful treatment with subantimicrobial-dose doxycycline // J. Drugs Dermatol. 2014. Vol. 13. N. 6. P. 763–765. PMID: 24918570.

Smith M., Wolffsohn J.S., Chiang J.C.B. Topical ivermectin 1.0% cream in the treatment of ocular demodicosis // Cont. Lens. Anterior Eye. 2024. Vol. 47. N. 1. Article ID 102099. DOI: https://doi.org/10.1016/j.clae.2023.102099. Epub 2023 Dec 3. PMID: 38049351.

Snapp R.H. Lewandowsky’s rosacea-like eruption; a clinical study // J. Invest. Dermatol. 1949. Vol. 13. N. 4. P. 175–190. DOI: https://doi.org/10.1038/jid.1949.86. PMID: 15391319.

Sobolewska B., Doycheva D., Deuter C.M. et al. Efficacy of topical ivermectin for the treatment of cutaneous and ocular rosacea // Ocul. Immunol. Inflamm. 2021. Vol. 29. N. 6. P. 1137–1141. DOI: https://doi.org/10.1080/09273948.2020.1727531. Epub 2020 Apr 7. PMID: 32255398.

Stein Gold L., Kircik L., Fowler J. et al.; Ivermectin Phase 3 Study Group. Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials // J. Drugs Dermatol. 2014. Vol. 13. N. 11. P. 1380–1386. PMID: 25607706.

Stein L., Kircik L., Fowler J. et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies // J. Drugs Dermatol. 2014. Vol. 13. N. 3. P. 316–323.

Taieb A., Ortonne J.P., Ruzicka T. et al.; Ivermectin Phase III Study Group. Superiority of ivermectin 1% cream over metronidazole 0·75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial // Br. J. Dermatol. 2015. Vol. 172. N. 4. P. 1103–1110. DOI: https://doi.org/10.1111/bjd.13408. Epub 2015 Feb 11. PMID: 25228137.

Tan J., Almeida L.M., Bewley A. et al. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel // Br. J. Dermatol. 2017. Vol. 176. N. 2. P. 431–438. DOI: https://doi.org/10.1111/bjd.15122. Epub 2017 Jan 23. PMID: 27718519.

Tan J., Schöfer H., Araviiskaia E. et al.; RISE Study Group. Prevalence of rosacea in the general population of Germany and Russia — the RISE study // J. Eur. Acad. Dermatol. Venereol. 2016. Vol. 30. N. 3. P. 428–434. DOI: https://doi.org/10.1111/jdv.13556. PMID: 26915718; PMCID: PMC5067643.

Tan J., Steinhoff M., Berg M. et al.; Rosacea International Study Group. Shortcomings in rosacea diagnosis and classification // Br. J. Dermatol. 2017. Vol. 176. N. 1. P. 197–199. DOI: https://doi.org/10.1111/bjd.14819. PMID: 28098383.

Thibaut de Ménonville S., Rosignoli C., Soares E. et al. Topical treatment of rosacea with ivermectin inhibits gene expression of cathelicidin innate immune mediators, LL-37 and KLK5, in reconstructed and ex vivo skin models // Dermatol. Ther. (Heidelb.). 2017. Vol. 7. N. 2. P. 213–225. DOI: https://doi.org/10.1007/s13555-017-0176-3. Epub 2017 Feb 27. PMID: 28243927; PMCID: PMC5453918.

Thiboutot D., Anderson R., Cook-Bolden F. et al. Standard management options for rosacea: The 2019 update by the National Rosacea Society Expert Committee // J. Am. Acad. Dermatol. 2020. Vol. 82. N. 6. P. 1501–1510. DOI: https://doi.org/10.1016/j.jaad.2020.01.077. Epub 2020 Feb 7. PMID: 32035944.

Two A.M., Wu W., Gallo R.L., Hata T.R. Rosacea: part I. Introduction, categorization, histology, pathogenesis, and risk factors // J. Am. Acad. Dermatol. 2015. Vol. 72. N. 5. P. 749–758. DOI: https://doi.org/10.1016/j.jaad.2014.08.028. PMID: 25890455.

US Food and Drug Administration. Mirvaso (brimonidine) gel, 0.33%, for topical use: prescribing information. 2013. URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204708lbl.pdf (дата обращения: 16.08.2023).

URL: https://eyewiki.org/Morbihan_Disease

Van Zuuren E.J., Arents B.W.M., van der Linden M.M.D. et al. Rosacea: new concepts in classification and treatment // Am. J. Clin. Dermatol. 2021. Vol. 22. N. 4. P. 457–465. DOI: https://doi.org/10.1007/s40257-021-00595-7. Epub 2021 Mar 23. PMID: 33759078; PMCID: PMC8200341.

Van Zuuren E.J., Fedorowicz Z., Tan J. et al. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments // Br. J. Dermatol. 2019. Vol. 181. N. 1. P. 65–79. DOI: https://doi.org/10.1111/bjd.17590. Epub 2019 Mar 10. PMID: 30585305; PMCID: PMC6850438.